NCT01031472View on ClinicalTrials.gov

A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 21, 2009

Primary Completion Date

March 11, 2010

Study Completion Date

March 11, 2010

Conditions
Infection, Human Immunodeficiency VirusHIV Infections
Interventions
DRUG

GSK2248761 formulation 1

100mg GSK2248761 formulation 1- fasted 100mg GSK2248761 formulation 1 - with food (moderate fat meal)

DRUG

GSK2248761 reference formulation

GSK2248761 100mg Gelucire reference capsule with food

DRUG

GSK2248761 formulation 3

100mg GSK2248761 formulation 3 fasted 100mg GSK2248761 formulation 3 with food (moderate fat meal)

DRUG

GSK2248761 formulation 2 or 4

100mg GSK2248761 formulation 2 or 4 - fasted 100mg GSK2248761 formulation 2 or 4 - with food (moderate fat meal)

Trial Locations (1)

14202

GSK Investigational Site, Buffalo

Sponsors

Lead Sponsor

ViiV Healthcare

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY